GlaxoSmithKline CEO Andre Witty gives his view on what pharma must do to stay competitive in the future, but he leaves out useful information on innovating with few resources in a competitive environment.
Market Access is a Changing – Map Stakeholders to Understand Payor Policies
11/23/2010 By Leave a Comment
Writing an article about market forces and issues facing the Pharmaceutical industry is easy. But Mark Halliday in his recent article “Success Factors for Market Access in the Pharmaceutical Industry” has put together a collection of ideas to to improve market access. Mark talks about the need to recognize the market has fragmented, and then… more »
The Persistent Myth of the Lone Inventor
10/20/2010 By Leave a Comment
![51bfJbi7uaL._SL500_AA300_[1]](http://www.lnxresearch.com/blog/wp-content/uploads/2010/10/51bfJbi7uaL._SL500_AA300_1-90x90.jpg "51bfJbi7uaL._SL500_AA300_[1]")
Contrary to popular belief, invention is a team sport. “Innovation doesn’t come just from giving people incentives; it comes from creating environments where their ideas can connect.”
Social Norms in Large and Small Networks
10/14/2010 By 1 Comment
A summary of Robert Hanson’s thoughts and implications how community network size impacts social norms
“Global Top 20” Shows US and UK Have the Most Influential Experts in Breast Cancer Research
10/01/2010 By Leave a Comment
Twitter, Facebook, and Social Activism: NewYorker.com
09/28/2010 By Leave a Comment
Malcom Gladwell’s recent article “Twitter, Facebook, and Social Activism” in the New Yorker provides food for thought about the nature and value of weak social ties versus strong ties
Vicious Cycle or Virtuous Cycle? Thought Leaders Debate the Value of Thought Leaders
09/20/2010 By Leave a Comment
Where should we draw the line between considering pharmaceutical key opinion leaders as thought leaders vs. calling them “influence peddlers”? A recent article published in “The Chronicle of Higher Education” casts aspersions on the entire protocol of co-mingling powerful KOLs, medical doctors and the academic research community within the context of drug development. We disagree…
Proximity influences behavior and adoption rates
09/10/2010 By Leave a Comment
What’s better, more tightly clustered friends or more diverse friends in your social network? A recent article looks at behavioral adoption among social network models…
Report from KOL Relationship Summit
08/26/2010 By Leave a Comment
![liberty_bell_1[1]](http://www.lnxresearch.com/blog/wp-content/uploads/2010/08/liberty_bell_11-90x90.jpg "liberty_bell_1[1]")
You couldn’t tell it was conference host eXL Pharma’s first year foray into a new subject area: KOL Relationship Summit. The dialogue amongst the audience and speakers was top notch – all too often, a conference is a series of talking heads, but that was not the case.